Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2025-03-10
Target enrollment:
Participant gender:
Summary
Prolgolimab is an anti-PD-1 inhibitor that has previously been shown to be effective and safe
for the treatment of patients with melanoma. Given the mechanism of action, it is expected to
be effective in patients with classical Hodgkin lymphoma (cHL).
The use of PD-1 inhibitors in 2nd line treatment, as part of PET-adapted
monotherapy/combination therapy, has already demonstrated a favorable toxicity profile, as
well as a high efficacy, which may lead to increased survival of patients with r/r cHL. It
has been demonstrated that long-term disease remission can be achieved after PD-1 inhibitor
therapy, even in a group of heavily pretreated patients with relapsed/refractory cHL. The use
of prolgolimab as part of PET-adapted therapy strategy in this study may allow to achieve a
prolonged remission in patients with cHL who are highly sensitive to immunotherapy while
omitting the autologous stem cell transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
St. Petersburg State Pavlov Medical University
Collaborator:
N.N. Petrov National Medical Research Center of Oncology